Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDA-201 in Relapsed/Refractory B-Cell NHL
NCT05296525Phase 2Terminated
- Sponsor
- Gamida Cell
- Start
- Jul 2022
- Primary completion
- Apr 2024
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of nicotinamide-expanded natural killer cells in B-cell non-Hodgkin lymphoma, follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), sponsored by Gamida Cell. Started Jul 2022; status: terminated.
02
Drugs
nicotinamide-expanded natural killer cells
03
Conditions
B-cell non-Hodgkin lymphomafollicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT05296525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05296525.